<DOC>
	<DOCNO>NCT02508064</DOCNO>
	<brief_summary>This 2-part study determine bioavailability BMS-626529 healthy subject prototype low dose extend release formulation ( Part 1 ) BMS-663068 prototype extend release multi-particulate formulation ( Part 2 ) BMS-663068 relative 600 mg extend release tablet BMS-663068 .</brief_summary>
	<brief_title>Bioavailability BMS-626529 Healthy Subjects From Prototype Low Dose Extended Release Formulations ( Part 1 ) Prototype Extended Release Multi-particulate Formulations ( Part 2 ) BMS-663068 Relative 600 mg Extended Release Tablet</brief_title>
	<detailed_description />
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Males female , 18 50 year age , inclusive Healthy subject determine clinically significant deviation normal medical surgical history , PE finding , vital sign measurement , 12lead ECG measurement , physical measurement , clinical laboratory test result Women childbearing potential ( WOCBP ) must negative urine pregnancy test ( performed female ; minimum sensitivity 25 IU/L equivalent unit human chorionic gonadotropin ) within 24 hour prior start study drug Any significant acute chronic medical illness Evidence organ dysfunction clinically significant deviation normal PE , vital sign , ECG , clinical laboratory determination beyond consistent target population Any follow 12lead ECG prior study drug administration , confirm repeat : ) PR ≥ 210 msec ii ) QRS ≥ 120 msec iii ) QT ≥ 500 msec iv ) QTcF ≥ 450 msec Exposure investigational drug placebo within 12 week study drug administration Positive blood screen hepatitis C antibody ( HCV Ab ) , hepatitis B surface antigen ( HBsAg ) , HIV1 HIV2 antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>